FDA Demands Tobacco Companies Prove They Sold Here First
Published Date: 9/29/2025
Notice
Summary
The FDA is asking for approval to collect info from tobacco companies about how they prove their products were sold in the U.S. This helps make sure only legal tobacco products are on the market. Tobacco businesses should get ready for new paperwork soon, but no big costs are expected right now.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Tobacco firms must ready new paperwork
The FDA is asking OMB to approve a new information collection under the Paperwork Reduction Act of 1995 that asks tobacco companies to show how their products were commercially marketed in the United States. Tobacco businesses should prepare for new paperwork soon, though the FDA says no big costs are expected right now.
Aims to keep only legal tobacco for sale
The FDA says the information collection is meant to help ensure that only tobacco products that were legally commercially marketed in the United States remain on the market. If effective, this action is intended to reduce the presence of illegally marketed tobacco products.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-18803, Presidential Declaration of a Major Disaster for Public Assistance Only for the State of Kansas
The President has declared a major disaster in Kansas because of severe storms, tornadoes, and flooding. This means local communities can get special help to fix public buildings and services. The aid starts right away to help Kansas bounce back faster and stronger.
Next: 2025-18809, Determination of Regulatory Review Period for Purposes of Patent Extension; NIKTIMVO
The FDA has officially set the review period for NIKTIMVO, a human biological product, so its patent can be extended. This helps the company behind NIKTIMVO get extra time to protect their invention. If you’re involved in patents or drug development, this timing update matters for planning and legal steps.